Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Tucatinib
Related studies linked through entity extraction aliases.
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- EARLY_PHASE1
Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.
- Status
- COMPLETED
- Phase
- N/A
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE2
Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
PRE-I-SPY Phase I/Ib Oncology Platform Program
- Status
- RECRUITING
- Phase
- PHASE1
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
- Status
- RECRUITING
- Phase
- PHASE2
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study
- Status
- WITHDRAWN
- Phase
- PHASE2
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2